We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy

SCIENTIFIC PUBLICATIONS

Our medical oncologists and laboratory investigators are at the forefront of investigations into the causes of cancer and the search for novel treatments.

We have published the results of our investigations, often in collaboration with some of the most prestigious international institutions, in renowned medical journals such as the New England Journal of Medicine, Clinical Cancer Research, and many others.

CONSULT OUR SCIENTIFIC PUBLICATIONS

01/09/2017

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

AUTHORS Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, Reguart N, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

PUBLICATION J Nat. Cancer Inst. Sep 1;109(9).

READ ARTICLE

26/06/2017

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer

AUTHORS Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.

PUBLICATION Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. Epub 2017 May 18.

READ ARTICLE

15/06/2017

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)

AUTHORS Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J, Archila P, Martín C, Corrales L, Cuello M, Ortiz C, Pino LE, Rosell R, Zatarain-Barrón ZL; CLICaP.

PUBLICATION Target Oncol. 2017 Jun 15. [Epub ahead of print]

READ ARTICLE

01/06/2017

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib

AUTHORS Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

PUBLICATION Lung Cancer. 2017 Jun;108:154-160. Epub 2017 Mar 22.

READ ARTICLE

01/06/2017

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

AUTHORS Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.

PUBLICATION J Natl Cancer Inst. 2017 Jun 1;109(6).

READ ARTICLE